
Sean Mcgarry
Examiner (ID: 6820, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1674, 1621, 1809, 1624, 1805 |
| Total Applications | 1927 |
| Issued Applications | 1068 |
| Pending Applications | 344 |
| Abandoned Applications | 554 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17595773
[patent_doc_number] => 20220145347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => HIGH-EFFICIENCY RECONSTITUTION OF RNA MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/486488
[patent_app_country] => US
[patent_app_date] => 2021-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486488
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/486488 | High-efficiency reconstitution of RNA molecules | Sep 26, 2021 | Issued |
Array
(
[id] => 17807765
[patent_doc_number] => 20220259600
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/484386
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39621
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484386 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | Sep 23, 2021 | Abandoned |
Array
(
[id] => 17334572
[patent_doc_number] => 20220000903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => PHARMACEUTICAL COMPOSITION THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B, AND SCREENING METHOD
[patent_app_type] => utility
[patent_app_number] => 17/483183
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/483183 | PHARMACEUTICAL COMPOSITION THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B, AND SCREENING METHOD | Sep 22, 2021 | Abandoned |
Array
(
[id] => 17776851
[patent_doc_number] => 20220243200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/481679
[patent_app_country] => US
[patent_app_date] => 2021-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481679
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/481679 | COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION | Sep 21, 2021 | Pending |
Array
(
[id] => 17312823
[patent_doc_number] => 20210401871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => OLIGONUCLEOTIDES TO TREAT EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/475795
[patent_app_country] => US
[patent_app_date] => 2021-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11798
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475795
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/475795 | OLIGONUCLEOTIDES TO TREAT EYE DISEASE | Sep 14, 2021 | Abandoned |
Array
(
[id] => 17314859
[patent_doc_number] => 20210403907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => ARC-BASED CAPSIDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/473209
[patent_app_country] => US
[patent_app_date] => 2021-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32078
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473209
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/473209 | ARC-BASED CAPSIDS AND USES THEREOF | Sep 12, 2021 | Abandoned |
Array
(
[id] => 17609802
[patent_doc_number] => 20220152081
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS
[patent_app_type] => utility
[patent_app_number] => 17/469530
[patent_app_country] => US
[patent_app_date] => 2021-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469530
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/469530 | Agents and methods for treating pancreatic ductal adenocarcinomas | Sep 7, 2021 | Issued |
Array
(
[id] => 20077548
[patent_doc_number] => 12351598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-08
[patent_title] => Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
[patent_app_type] => utility
[patent_app_number] => 17/461797
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 105
[patent_figures_cnt] => 181
[patent_no_of_words] => 83131
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461797
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/461797 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Aug 29, 2021 | Issued |
Array
(
[id] => 17314872
[patent_doc_number] => 20210403920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
[patent_app_type] => utility
[patent_app_number] => 17/411265
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14807
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411265
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411265 | Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer | Aug 24, 2021 | Issued |
Array
(
[id] => 17292524
[patent_doc_number] => 20210388363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA
[patent_app_type] => utility
[patent_app_number] => 17/411932
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411932
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411932 | Modulators and modulation of the receptor for advanced glycation end-products RNA | Aug 24, 2021 | Issued |
Array
(
[id] => 17414351
[patent_doc_number] => 20220049255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => MODULATING THE CELLULAR STRESS RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/411313
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30871
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411313
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411313 | Modulating the cellular stress response | Aug 24, 2021 | Issued |
Array
(
[id] => 19975901
[patent_doc_number] => 12343357
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Compositions and methods for modulating MECP2 expression
[patent_app_type] => utility
[patent_app_number] => 17/408920
[patent_app_country] => US
[patent_app_date] => 2021-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 17727
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17408920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/408920 | Compositions and methods for modulating MECP2 expression | Aug 22, 2021 | Issued |
Array
(
[id] => 17720755
[patent_doc_number] => 20220213475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => DUAL TARGETING siRNA AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/402459
[patent_app_country] => US
[patent_app_date] => 2021-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402459
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/402459 | DUAL TARGETING siRNA AGENTS | Aug 12, 2021 | Abandoned |
Array
(
[id] => 17256842
[patent_doc_number] => 20210369827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => COMBINATION OF VACCINATION AND OX40 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/396760
[patent_app_country] => US
[patent_app_date] => 2021-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32599
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396760
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/396760 | Combination of vaccination and OX40 agonists | Aug 7, 2021 | Issued |
Array
(
[id] => 17200076
[patent_doc_number] => 20210340171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => ANTISENSE NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/375877
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/375877 | ANTISENSE NUCLEIC ACIDS | Jul 13, 2021 | Abandoned |
Array
(
[id] => 17312903
[patent_doc_number] => 20210401951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => MRNA THERAPY FOR POMPE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/369783
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/369783 | MRNA therapy for pompe disease | Jul 6, 2021 | Issued |
Array
(
[id] => 17299909
[patent_doc_number] => 20210395748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/366835
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366835
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366835 | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors | Jul 1, 2021 | Issued |
Array
(
[id] => 17505480
[patent_doc_number] => 20220098582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => Methods for Treatment of Alport Syndrome
[patent_app_type] => utility
[patent_app_number] => 17/366796
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366796
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/366796 | Methods for Treatment of Alport Syndrome | Jul 1, 2021 | Abandoned |
Array
(
[id] => 18825415
[patent_doc_number] => 11840686
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Modulation of prekallikrein (PKK) expression
[patent_app_type] => utility
[patent_app_number] => 17/367096
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 66203
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367096 | Modulation of prekallikrein (PKK) expression | Jul 1, 2021 | Issued |
Array
(
[id] => 18552429
[patent_doc_number] => 20230250438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => Blood-Brain Barrier Penetrating Aptamer and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 18/013055
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9696
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013055
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/013055 | Blood-Brain Barrier Penetrating Aptamer and Use Thereof | Jun 28, 2021 | Pending |